Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Our AI ranks Axogen, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Axogen, Inc. is a small-cap company with a market capitalization of $1.86B. It ranks number 6 by market capitalization among the 30 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast.
For AXGN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 21.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 36.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, AXGN included.
Follow AXGN free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
| Metric | AXGN | Rank |
|---|---|---|
| Market Cap | $1.86B | 6/30 |
| P/B Ratio | 7.26x | 5/23 |
| EPS | $-0.38 | – |
| Book Value/Share | $4.77 | – |
| Revenue/Share | $4.67 | – |
| FCF/Share | $0.16 | – |
| Metric | AXGN | Rank |
|---|---|---|
| ROIC | -4.7% | 14/23 |
| Gross Margin | 74.6% | 8/27 |
| Operating Margin | -5.1% | 13/28 |
| EBT Margin | -5.1% | 13/28 |
| Tax Rate | 0.0% | – |
| Metric | AXGN | Rank |
|---|---|---|
| Current Ratio | 6.60x | 6/30 |
| Quick Ratio | 5.04x | 7/29 |
| D/E Ratio | 0.19x | 22/25 |
| Financial Leverage | 1.19x | 23/25 |
| Interest Coverage | -3.4x | 13/30 |
| Working Capital | $170M | 8/29 |
| Metric | AXGN | Rank |
|---|---|---|
| Operating Cash Flow | $15M | 8/30 |
| Free Cash Flow | $9M | 5/14 |
| Capital Spending | -$6M | 10/14 |
| OCF Growth YoY | 109.4% | 1/9 |
| FCF Growth YoY | 74.0% | 2/6 |
| FCF/Sales | 3.4% | 6/14 |
| CapEx/Sales | 2.6% | 6/14 |
| Metric | AXGN | Rank |
|---|---|---|
| Asset Turnover | 0.82x | 8/19 |
| Receivables Turnover | 7.4x | 6/20 |
| Inventory Turnover | 1.4x | 21/27 |
| Fixed Assets Turnover | 3.0x | 18/20 |
| Days Sales Outstanding | 50 days | 14/20 |
| Days Inventory | 270 days | 7/27 |
| Payables Period | 162 days | 8/24 |
| Cash Conversion Cycle | 158 days | 9/19 |
| Metric | AXGN | Rank |
|---|---|---|
| Total Revenue | $251M | 5/19 |
| Operating Income | -$13M | 22/30 |
| R&D Expense | $36M | 6/28 |
| SG&A Expense | $247M | 4/26 |
| Cost of Goods Sold | $64M | 8/27 |
| Metric | AXGN | Rank |
|---|---|---|
| Shares Outstanding | 54M | – |
| Total Current Assets | $200M | 65.7% of assets |
| Cash & Short-term Investments | $95M | 31.0% of assets |
| Accounts Receivable | $34M | 11.2% of assets |
| Inventory | $47M | 15.5% of assets |
| Total Liabilities | $49M | 15.9% of assets |
| Short-term Debt | $2M | 0.6% of assets |
Companies classified under the same SEC industry code as Axogen, Inc. (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| AXGN Axogen, Inc. | ▲ | $1.86B |
| MDT Medtronic Plc | ▼ | $121.20B |
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.45B |
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| CNMD Conmed Corp | ▼ | $1.40B |
| CBLL Ceribell, Inc. | ▲ | $961M |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $323M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| VANI Vivani Medical, Inc. | ▶ | $104M |
| STXS Stereotaxis, Inc. | ▶ | $101M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $77M |
| OM Outset Medical, Inc. | ▲ | $77M |
| ECOR Electrocore, Inc. | ▲ | $71M |
| POSC Positron Corp | ▲ | $53M |
| VASO Vaso Corp | ▲ | $51M |
| POCI Precision Optics Corporation, Inc. | ▲ | $48M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| ITOC Itonic Holdings Ltd | ▶ | $29M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| ADMT Adm Tronics Unlimited, Inc. | ▼ | $3M |
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| NUWE Nuwellis, Inc. | ▶ | $2M |
| ESMC Escalon Medical Corp | ▶ | $1M |
| HCIL Hongchang International Co., Ltd | ▶ | N/A |
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Good morning. Joining me on today's call is Michael Dale, AxoGen's Chief Executive Officer and Director; and Lindsey Hartley, Chief Financial Officer. Michael will discuss third quarter 2025 financial ...
Our AI ranks Axogen, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For AXGN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 21.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 36.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Axogen, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
32 issuers in our coverage, AXGN included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Conmed Corp (CNMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.